924P - Identification of exosomes in non-Hodgkin B-cell lymphomas. Prognostic usefulness in patients treated with rituximab-chemotherapy: a prospective, m...

Date 08 October 2016
Event ESMO 2016 Congress
Session Poster Display
Topics Lymphomas
Presenter Mariano Provencio
Citation Annals of Oncology (2016) 27 (6): 313-327. 10.1093/annonc/mdw375
Authors M. Provencio1, M. Rodriguez-Balada2, B. Cantos3, C. Quero4, R. García Arroyo5, A. Rueda6, C. Maximiano3, D. Rodriguez Abreu7, A. Sanchez8, V. Garcia8
  • 1Medical Oncology, Hospital Universitario Puerta de Hierro Majadahond, 28222 - Majadahonda/ES
  • 2Pathology, University Hospital St. Joan de Reus, Reus/ES
  • 3Medical Oncology, Hospital Universitario Puerta de Hierro, 28222 - Madrid/ES
  • 4Medical Oncology, Hospital Universitario Virgen de la Victoria, Malaga/ES
  • 5Medical Oncology, Complejo Hospitalario de Pontevedra, 36004 - Pontevedra/ES
  • 6Medical Oncology, Hospital Costa del Sol, 29602 - Malaga/ES
  • 7Medcal Oncology Service, Hospital Universitario Insular de Gran Canaria, 35016 - Las Palmas/ES
  • 8Medical Oncology, Hospital Universitario Puerta de Hierro, Madrid/ES



To determine the presence of mRNAs (C-MYC, BCL-XL, BCL-6, NF-κß, PTEN and AKT) in exosomes of plasma from patients with B-Cell Lymphoma, and its relationship with their response to rituximab-based chemotherapy and survival.


Exosomes were isolated of 98 patients with B-cell Lymphoma and 68 healthy controls. mRNAs were analyzed by quantitative PCR. 31 post-treatment samples were also studied.


Exosome levels were not associated with response to treatment and outcome of patients. In general series and follicular lymphomas (FL), presence of AKT mRNA was associated with non-response to rituximab-based treatment. Patients with first relapse or disease progression showed a lower percentage of presence of PTEN and BCL-XL mRNA. Presence of BCL-6 mRNA was associated with high rate of death of patients. Absence of PTEN mRNA, in general series, and presence of C-MYC mRNA, in FL, was associated with short Progression-Free Survival. BCL-6 and C-MYC mRNA were independent prognostic variables for OS. C-MYCmRNA interacted with response to treatment, giving prognostic value for OS in non responsive patients. In post-treatment samples, presence of BCL-XL mRNA was associated with high rate of death; and appearance of BCL-6 mRNA and loss of PTENmRNA were associated with non-response to treatment.


It is possible to identify exosomes in plasma of lymphoma patients. This may assist in prognosis, both at the start of treatment and during follow-up, and in identification of those patients at greater risk of progression. In both situations, the presence of BCL-6 identifies the patients with worse prognosis.

Clinical trial identification

Legal entity responsible for the study



Spanish Lymphoma Oncology Group (GOTEL).


All authors have declared no conflicts of interest.